Anthem Biosciences , a leading drug discovery and manufacturing services company, has seen its shares soar by 46% since its listing on July 21, with an additional 11% boost following the announcement of robust June-quarter results on August 13. The company's impressive financial performance and ambitious expansion plans have caught investors' attention.

Strong Q1 Financial Results

Anthem Biosciences reported stellar financial results for the first quarter:

The company's operating margin slightly decreased to 38.10% from 39.20%, primarily due to share-based compensation charges of ₹4.40 crore.

Expansion and Growth Strategies

Anthem Biosciences is actively pursuing expansion strategies to capitalize on market opportunities:

1. Capacity Expansion: The company is increasing its production capacity by 155 kilolitres, aiming to reach a total capacity of 425 kilolitres by September 2025. In the June quarter alone, 54 kilolitres were added.

2. Product Portfolio Growth: Two new products received approval, expanding the commercial portfolio from 10 to 12 products.

3. Revenue Projection: Anthem Biosciences expects a 20% annual revenue growth for FY26, showcasing confidence in its business model and market demand.

4. Backward Integration: The company has successfully completed backward integration on a key molecule, potentially improving cost efficiency and supply chain control.

5. GLP-1 Drug Development: Anthem is developing GLP-1 obesity and diabetes drugs, targeting opportunities as patents expire in multiple markets.

Recent Corporate Developments

According to the latest LODR (Listing Obligations and Disclosure Requirements) data, Anthem Biosciences recently conducted a postal ballot through remote e-voting. The company announced on September 15, 2025, that the resolutions set out in the postal ballot notice were approved by the members with the requisite majority. The resolutions are deemed to have been passed on September 12, 2025.

This corporate action demonstrates Anthem Biosciences' commitment to shareholder engagement and transparency in its decision-making processes.

Conclusion

Anthem Biosciences' strong financial performance, coupled with its strategic expansion plans and focus on innovation, has resonated well with investors. The company's efforts in capacity expansion, product portfolio diversification, and development of new drug candidates position it favorably for future growth in the competitive pharmaceutical services sector.

As Anthem Biosciences continues to execute its growth strategy, investors and industry observers will be keenly watching its progress in maintaining this momentum and capitalizing on emerging opportunities in the drug discovery and manufacturing services market.

Anthem Biosciences Limited, a leading contract research, development, and manufacturing organization (CRDMO), has reported robust financial results for the first quarter of fiscal year 2026, marking its first earnings report since going public.

Financial Highlights

• Consolidated revenue reached INR 540.00 crores, representing a significant 60% year-on-year growth.
• The Contract Research, Development, and Manufacturing (CRDM) business contributed INR 452.70 crores to the total revenue.
• Specialty ingredients segment generated INR 87.50 crores.
• EBITDA stood at INR 214.30 crores with a margin of 38%.
• Profit After Tax (PAT) was INR 135.80 crores, maintaining a 24% margin.
• The company reported a strong net cash position of INR 784.80 crores as of June 30, 2025.

Operational Highlights

• Two molecules progressed from Phase 3 to commercial stage, expanding the commercial portfolio from 10 to 12 products.
• The company added 54 kiloliters of custom synthesis capacity in unit 2 during the quarter.
• Anthem Biosciences maintains a healthy pipeline with 8 molecules currently in Phase 3 clinical trials.

Business Outlook

Ajay Bhardwaj, Managing Director and CEO of Anthem Biosciences, commented on the results, stating, "We have kicked off FY26 with a strong performance, laying a solid foundation for the year ahead. The growth reflects our CRDM revenue stream that started ramping up in Q2 of FY25."

The management expects to maintain historical growth rates of around 20% annually, although they noted that this quarter was exceptional due to the lumpy nature of their business. The growth was primarily driven by increased demand for commercial products across multiple customers.

Capacity Expansion Plans

Anthem Biosciences is continuing its capacity expansion efforts:

• An additional 76 kiloliters of custom synthesis capacity is expected to be completed in unit 2 by the end of the calendar year.
• 25 kiloliters of capacity, including peptide synthesis, will be added in NeoAnthem by the end of the first half of the fiscal year.
• 40 kiloliters of fermentation capacity will be added in NeoAnthem by the end of the calendar year.
• The company has initiated groundbreaking for its unit 4 expansion.

Market Position and Future Outlook

Anthem Biosciences maintains a strong position in the CRDMO space, with a focus on innovative pharmaceuticals. The company is actively working on new modalities such as Antibody-Drug Conjugates (ADCs) and has full capabilities across multiple projects in this area.

The management remains optimistic about future growth prospects, citing ongoing discussions with customers for potential expansion of wallet share and participation in emerging areas such as GLP-1 agonists.

As Anthem Biosciences continues to invest in new technologies and capacity expansion, it aims to strengthen its position as a key player in the global pharmaceutical outsourcing market.